The cancer-drug market is zooming fast towards the $100 billion mark, according to a new study conducted by the health care research network IMS Institute for Healthcare Informatics. In 2014, the global oncology market spent almost $90 billion, and it’s growing in a swift pace at a 5 percent clip annually.
For the followers of the cancer industry, this is undoubtedly good news. This could also mean progress, and that the world is showing no sign of apathy over finding the elusive cancer treatment. This, in turn, gives hope to cancer patients and their families, ensuring them that cancer is not yet a lost cause.
For the oncology market—the drug makers, doctors, the hospital owners, and its investors—it’s a milestone. It means growth, and that their money is in the right place.
But behind this landmark is an inconvenient truth: most new cancer drugs today are expensive to an extent that they become inaccessible and unaffordable to most patients. In the United States, a patient has to make $10,000 just to afford a complete monthly cancer treatment. In 2014, the overall cost for cancer treatments per month was only playing around $5,000, a trend that experts attribute to new, expensive cancer drugs on the market.
It was only in 2013 when American oncologists spoke against the skyrocketing prices of cancer drugs. It was rather late compared with other countries with smaller economies like India and the Philippines, where there have been laws on imposing reasonable price cuts to all types of medicines. According to the leaders of the American Society of Clinical Oncology, this trend contributes to the patient’s suffering: facing the fatal illness means facing bankruptcy as well.
Indeed, the milestone is more of a challenge.
Along with the soaring oncology market is the growing biotech industry. In 2014, 81 new companies went public, which is 90 percent higher from 2013. What fuels the growth is the sudden increase of the immune-oncology market, which is shared by established pharmaceutical firms and emerging biotech companies focused on developing new treatments for cancers.
But hopes are bestowed more upon emerging biotech firms that promise to offer cheaper alternatives. For every new biotech firm on the market comes new expectation towards cheaper drugs in the future.
Nascent Biotech, Inc. (OTC:NBIO) is one of them. The California-based company is not only focused on developing human antibodies and cytokine responses for cancer treatment. It is also looking for ways that will make cancer treatment more effective, less painful, and cheaper.
Oncology, at the end of the day, is a business endeavor—a multimillion-dollar one. It is a very large industry shared by insurers, companies, medical groups, non-profit organizations, doctors, hospitals, research groups, investors, experts, watchdogs, politicians, and entrepreneurs.
But it goes without saying that what the entities outside the industry—patients and devoted doctors—want is one simple thing: a sincere dedication to alleviate their sufferings, be it physically, emotionally, or even financially.
The growing oncology market must translate to cheaper, more affordable but efficient cancer drugs.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
Scientific study finds digital games like Minecraft as educational as off-screen play
Miami Yacht Show announces relocation for 31st event next year
Study says happiness in wealth higher among those who rightfully earned it
Enjoy travel more by avoiding screen addiction
Protect your productivity from time-wasters in 7 ways
Cannabis acceptance grows as hemp industry leader PotNetwork Holding breaks CBD sales records
This fast-growing organic products stock already has space on Whole Foods’ shelves
Why Vapor Group Inc. might be the breakout penny stock you’ve been looking for in 2018
The CBD industry is enjoying a boost from the lifestyle sector
When you should consult your financial advisor
Promoting women’s football in Malta by UEFA projects
Euro NCAP marks its 20th anniversary with two crash tests
European Parliament’s International Trade Committee backs CETA
The American Heart Association has released four new PSAs
PwC presents 20th global CEO survey results in Switzerland
Crypto2 days ago
Could Global Blockchain Technologies change the way we invest in cryptocurrency?
Featured3 days ago
CBD stocks emerge strong in the growing cannabis industry, marijuana legalization
Crypto2 days ago
One of America’s oldest gold mines enters the crypto-century
Featured2 days ago
This hemp market player’s growth is about to go into overdrive
Business4 days ago
Disney announces price hikes for Disneyland tickets in the US
Featured3 days ago
The gig economy has matured — when will the business world catch up?
Business4 days ago
Delving deeper into the Internet of Things
Economy5 days ago
Economics, science, and religion: What role do humans play?